Reinach, March 16, 2021 - Evolva (SIX:EVE), has published today the agenda for its Annual General Meeting to be held on April 8, 2021. Physical attendance by shareholders is not permitted. Shareholders may cast their votes by the authorized independent proxy (please consult the invitation for further information).
With the necessary commercial building blocks in place following the US approval of nootkatone in August 2020, the launch of L-arabinose, and customer demand rising in Health Ingredients (order intake: +71% compared to 2019), the company is now fully focused on further strengthening manufacturing and supply chain.
Increase of Authorized Capital
At the end of 2020 Evolva still had cash and cash equivalents in the amount of CHF 19.7 million but requires additional financial resources to strenghten manufacturing and supply chain, and reach cash break-even (positive EBITDA) by 2023. The company therefore proposes to increase the current authorized capital in the maximum amount of CHF 2'968'782.35 (respectively maximum of 59'375'647 registered shares) by CHF 4'634'391.20 to the new maximum amount of CHF 7'603'173.55 (respectively maximum of 152'063'471 registered shares).
Elections of the Chairman and of the Board of Directors
The following individuals are proposed to be re-elected as Members of the company's Board of Directors: Beat In-Albon as Chairman as well as Richard Ridinger and Stephan Schindler as Members of the Board of Directors.
Christoph Breucker is proposed as new candidate.
Elections to the Compensation Committee
The Evolva Board of Directors proposes to elect Richard Ridinger, Stephan Schindler and Christoph Breucker as Members of the Compensation Committee.
Election of the Auditors
The Board of Directors proposes to elect Mazars Ltd., Zurich, as auditors.
Documents for the AGM, including the information notice with a full agenda and the proposals of the Board of directors, are available online at evolva.com/shareholder-info/annual-general-meeting-of-shareholders/.
Update Convertible Loan with Nice & Green SA
In addition, in order to cover present and future share delivery obligations under the convertible loan agreement with Nice & Green SA, dated June 26, 2020, the company has issued 105'000'000 new shares out of authorized capital.
About Evolva
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva's employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at evolva.com.
Disclaimer
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
Contact
Barbara Duci
Head of Investor and Corporate Relations
+41 61 485 2003
+41 79 739 2636
barbarad@evolva.com